Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/s41598-018-22469-5.pdf
Reference33 articles.
1. Yang, J. & Zhang, W. New molecular insights into osteosarcoma targeted therapy. Curr. Opin. Oncol. 25, 398–406 (2013).
2. Kansara, M., Teng, M. W., Smyth, M. J. & Thomas, D. M. Translational biology of osteosarcoma. Nat. Rev. Cancer 14, 722–35 (2014).
3. Whelan, J. S. et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann. Oncol. 26, 407–14 (2015).
4. Bielack, S. S. et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J. Clin. Oncol. 33, 2279–87 (2015).
5. Messerschmitt, P. J. et al. Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin. Orthop. Relat. Res. 466, 2168–75 (2008).
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting the EphA2 pathway: could it be the way for bone sarcomas?;Cell Communication and Signaling;2024-09-09
2. Preclinical models for the study of pediatric solid tumors: focus on bone sarcomas;Frontiers in Oncology;2024-07-18
3. The Targeted Therapies for Osteosarcoma via Six Major Pathways;Current Molecular Pharmacology;2023-10-11
4. Research progress in the mechanism and treatment of osteosarcoma;Chinese Medical Journal;2023-08-31
5. Safe and effective use of cabozantinib and nivolumab in stabilizing disease progression of tissue sarcoma after multiple lines of standard therapy;Journal of Case Reports and Images in Oncology;2023-07-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3